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INVESTIGATIVE REPORT
Acta Derm Venereol 2008; 88: 15–19
Recent studies have identified 2 loss-of-function vari-
ants, R501X and 2282del4, in the filaggrin gene as pre-
disposing factors in the development of eczema. In this 
study, representing the first analysis of the variants in 
a Swedish population, we analysed transmission in 406 
multiplex eczema families with mainly adult patients. In 
accordance with previous studies we found association 
between the filaggrin gene variants and atopic eczema 
(p = 9.5×10–8). The highest odds ratio for the combined al-
lele, 4.73 (1.98–11.29), p = 3.6×10–8, was found for the sub-
group with a severe eczema phenotype, and association 
was also found with raised allergen-specific IgE, allergic 
asthma and allergic rhinoconjunctivitis occurring in the 
context of eczema. Our results support an important role 
for the filaggrin gene variants R501X and 2282del4 in the 
development and severity of atopic eczema and indicate a 
possible role for the subsequent progression into eczema-
associated phenotypes. Key words: eczema; atopic derma-
titis; genetic association; filaggrin; R501X; 2282del4.
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Eczema (1), previously also referred to as atopic dermati-
tis (OMIM#603165), is a chronic relapsing inflammatory 
skin disorder that results from a complex interaction of 
genetic and environmental factors. Eczema currently 
affects 10–20% of children and 1–3% of adults in wes-
ternized countries (2). Patients with eczema often have 
increased levels of specific and/or total IgE (3) and may 
develop other allergic diseases such as allergic asthma 
and allergic rhinoconjunctivitis.
The disease has a high familial occurrence, with twin 
studies showing concordance rates of 0.72–0.77 in mo-
nozygotic and 0.15–0.23 in dizygotic twin pairs (4, 5). 
Emerging evidence shows that barrier dysfunction is a 
major component in the pathogenesis of eczema (6), and 
genetic linkage studies indicate that the epidermal dif-
ferentiation complex (EDC), located on chromosome 1 
(1q21), contains susceptibility genes for eczema (7).
A recently published study on the fused gene family 
member filaggrin (FLG), located in the EDC, showed 
that the repeats in this gene are polymorphic and that 
the genetic variants, R510X and 2282del4, cause a loss 
of these repeats. This, in turn, leads to a full ichthyosis 
vulgaris phenotype if in a homozygote or compound 
heterozygote form and a milder phenotype if in a hetero-
zygote form (8). Furthermore, Palmer et al. (9) showed 
that these variants also increase susceptibility to eczema 
and eczema-associated asthma. The FLG gene encodes 
the profilaggrin protein, which is one of the main protein 
components of the keratohyalin granules within the up-
per cell layers of the epidermis. Upon terminal differen-
tiation of the granular cells, the profilaggrin protein is 
proteolytically processed into 10–12 filaggrin peptides, 
which aggregate to the keratin cytoskeleton and bring 
about formation of squames (10–12). Thus, filaggrin 
is an essential component in the process leading to the 
formation of a fully functional skin barrier.
In the present study, we aimed to analyse the fre-
quency of the R510X and 2282del4 variants and their 
association with eczema and associated phenotypes in 
a Swedish material. Using a well-characterized eczema 
family material consisting of 406 multiplex families 
with mainly adult eczema patients, we found a strong 
association with eczema, especially in patients with 
a severe phenotype. Association was also found with 
raised allergen-specific IgE, allergic asthma and allergic 
rhinoconjunctivitis occurring in the same families. 
MATERIALS AND METHODS
Patients
Eczema families were recruited during 1995–1997 at the derma-
tology departments of the Karolinska University Hospital and the 
Danderyd Hospital in Stockholm, Sweden. Families with at least 
two affected siblings were included, resulting in 406 multiplex 
families with 1514 individuals including 921 siblings with eczema. 
These individuals are a subsets of a larger material described pre-
viously (13) and 109 of the families in this study were used in a 
genome-wide linkage analysis published previously (14).
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All the siblings were diagnosed with eczema by the same 
dermatologist, based on clinical examination and according to 
the UK Working Party’s Diagnostic Criteria (15). An arbitrary 
score for the disease severity of eczema was obtained using the 
classification shown in Table II. A severe eczema phenotype 
was defined as severity scoring ≥ 4. Subjects were classified as 
having allergic asthma or allergic rhinoconjunctivitis based on 
physician’s diagnosis. Parents were included regardless of their 
atopic status, and clinical information was gathered through a 
questionnaire. Seventy-eight percent of the affected siblings 
had onset of eczema ≤ 2 years of age and the mean age of the 
affected siblings at the time of sampling was 29 years.
IgE quantification
In all affected siblings, the following measurements were 
performed:
• Total serum-IgE concentration using the Pharmacia CAP 
System, IgE FEIA (Pharmacia & Upjohn Diagnostics AB, 
Uppsala, Sweden). The phenotype "raised total IgE" was 
analysed as a qualitative variable, with age-specific cut-off 
values. The cut-offs were; 22.3 kU/l (9 months–5 years), 263 
kU/l (5–20 years) and 122 kU/l (> 20 years).
• IgE antibodies to Phadiatop, a mixture of inhalant allergens 
(Pharmacia CAP System PhadiatopFEIA). The Phadiatop 
was reported as either positive or negative.
• IgE antibodies to a mixture of relevant food allergens (hen’s 
egg white, cow’s milk, soya bean, peanut, fish and wheat 
flour) (fx5) (Pharmacia CAP System RAST FEIA). The 
RAST mixture was divided into 6 classes, where a concen-
tration < 0.35 kU/l represents a negative result (class 0).
Of the eczema-affected siblings, 38% had raised total IgE 
and 64% had increased allergen-specific IgE to food and/or 
inhalant allergens. On the basis of elevated specific IgE level, 
the siblings were divided into atopic eczema patients (n = 558) 
and non-atopic (n = 333), according to the revised nomencla-
ture of the World Allergy Organization (1). The frequency of 
associated phenotypes and characteristics of the siblings with 
eczema are summarized in Table I. 
The study was approved by the local ethics committee, con-
ducted according to Declaration of Helsinki principles, and all 
subjects gave their informed consent. Where a sibling was less 
than 18 years of age the parents gave their consent.
Genotyping
Genomic DNA was extracted from peripheral venous blood 
using a standard protocol. Genotyping was performed for FLG 
variants R501X and 2282del4 on all 1514 individuals in the 
family material. R501X genotyping was performed using Taq-
Man-based allelic discrimination assay (Applied Biosystems, 
Foster City, CA, USA). Allele-specific Taqman MGB probes 
were labelled with fluorescent dyes FAM and VIC, respectively. 
Polymerase chain reactions (PCR) were carried out in 384-
well plates with 5 ng of genomic DNA, 5 μl of a reaction mix 
containing the specific TaqMan assay solution (4 times diluted 
compared with the manufacturers manual) and 1X TaqMan 
Universal PCR Master Mix, No AmpErase UNG (Applied 
Biosystems). Amplification was done following the Taqman 
Universal PCR protocol (95ºC for 10 min, followed by 40 cycles 
at 92ºC for 15 sec and 60ºC for 1 min). Allelic discrimination 
was performed with the ABI PRISM® 7900HT Sequence 
Detection System and the SDS 2.2.1 sequence detection system 
program (Applied Biosystems). The 2282del4 genotyping and 
allelic discrimination was performed using a TaqMan-based 
assay (Applied Biosystems) as previously described (16).
Data and statistical analysis
A Pedigree Disequilibrium Test (PDT) was performed in order 
to evaluate the evidence for association between variants and 
the different phenotypes (17). PDT and odds ratios (OR) esti-
mates including 95% confidence interval (CI) were analysed 
using the UNPHASED program (3.0.7) (18). The OR for alleles 
was estimated relative to the most common allele. Population 
Hardy-Weinberg equilibrium (HWE) was evaluated using a χ2 
test as implemented in the zGenStat 1.128 software (Henric 
Zazzi), with a cut-off value of p > 0.01. None of the p-values 
presented are corrected.
RESULTS
We performed genotyping for FLG variants R501X and 
2282del4 on all 1514 individuals in the 406 pedigrees, 
with a success rate above 91% for both assays. None 
of the variants analysed deviated from HWE.
The overall allele frequency of the 2 variants in the 
study population was 0.027 in the case of R501X (0.020 
for parents and 0.032 for affected siblings) and 0.061 for 
2282del4 (0.048 and 0.070, respectively). The combined 
allele frequency was 0.068 in the parents and 0.096 in 
the affected siblings. Four homozygotes for R501X, 7 
homozygotes for 2282del4 and 2 compound heterozy-
gotes were present among the siblings.
The results of the PDT, estimated OR and 95% CI 
are presented in Table III. Both R501X and 2282del4 
were over-transmitted to the eczema affected siblings 
(p = 1.5×10–5 and p = 2.9×10–5), and the combined al-
leles (p = 1.3×10–6). Dividing the siblings into atopic 
Table I. Phenotype frequencies for the eczema affected siblings 
and sex ratios in the different phenotype groups
Phenotype
Siblings
n (%)
Sex ratio
M:F
Eczema 921 (100) 1:1.5
Atopic eczema 588 (64) 1:1.3
Non-atopic eczema 333 (36) 1:2.2
Severe eczema (severity scoring ≥ 4) 139 (15) 1:1.3
Eczema and allergic asthma 347 (38) 1:1.5
Eczema and allergic rhinoconjunctivitis 613 (67) 1:1.5
Eczema and raised total IgE 345 (38) 1:1.6
For further details on phenotype definitions, see Materials and Methods 
section.
Table II. Severity scoring of eczema
Factor Score
Age at onset ≤ 2 years 1
Hospitalization for eczema 1
Affected sitesa on examination
0 0
1–3 1
> 3 2
Raised total and/or allergen-specific IgE 1
Maximum score  = 5
aThe presence of eczema at one or both sites in bilateral structures was 
regarded as presence at one site.
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and non-atopic eczema subgroups, the atopic group 
showed an OR of 2.21 (1.50–3.25) for the combined 
allele (p = 9.5×10–8). In the non-atopic eczema group, 
there was no association with the 2 FLG variants.
Adding sex as a confounder in these analyses did not 
alter the association significantly (data not shown).
The FLG variants were even more over-transmitted 
to affected siblings in the severe eczema phenotype (se-
verity scoring ≥ 4), where the combined allele showed 
an OR of 4.73 (1.98–11.29) with p = 3.6×10–8.
The association found with the early-onset phenotype 
was comparable with the eczema group as a whole 
(combined allele p = 1.2×10–6, OR 2.09 (1.46–2.97)).
In addition to the analysis of association with eczema, 
we analysed associated phenotypes in the eczema fa-
milies. Association was found for increased total IgE, 
allergic asthma and allergic rhinoconjunctivitis, with 
the most significant result found for the R501X variant 
in allergic rhinoconjunctivitis, p = 2.7×10–12, OR 5.07 
(1.47–17.46).
The effect of FLG null status on the severity of the ec-
zema and associated phenotypes was further illustrated 
when we correlated the genotype of the affected siblings 
with the frequency of the phenotypes. For this analysis, 
one sibling from each family was randomly selected 
and only individuals with full genotype information 
were used. The frequency of the genotypes was, wild-
type = 313, either heterozygotes = 67 and homozygotes 
(or compound heterozygotes) = 6. As shown in Fig. 1, 
there was an increase in the severity and the frequency 
of most of the eczema-associated phenotypes in the 
heterozygotes compared with wild-type, and in the 
homozygotes compared with the heterozygotes.
DISCUSSION
Recently published studies on the EDC member FLG 
have identified 2 common loss-of-function variants, 
R501X and 2282del4, in this gene as causative factors 
in ichthyosis vulgaris and as major predisposing factors 
in the development of eczema and asthma in patients 
with eczema (8, 9). The association with eczema 
and associated phenotypes has now been replicated 
and extended in a number of populations in Western 
Europe (reviewed by Irvine (19)), and new predisposing 
variants have been identified including unique variants 
in the Japanese population (16, 20).
In the present study, representing the first analysis of 
FLG reported in a Swedish population, we present data 
that further reinforce the importance of FLG variants as 
susceptibility factors in eczema and eczema associated 
phenotypes.
In accordance with other family-based studies we 
found an over-transmission of the FLG variants in our 
material (21–24). There was a strong association with 
eczema, producing an OR of 2.68 (1.34–5.33) for the 
R501X variant (p = 1.5×10–5) and 1.85 (1.24–2.76) for 
the 2282del4 (p = 2.9×10–5).
As reported in some previous studies, we found that the 
association is mainly to the atopic subgroup of eczema 
patients (22, 24, 25). The carrier frequency of FLG null 
alleles among the subjects in the non-atopic group was ac-
tually slightly lower than in the eczema group as a whole, 
indicating that these variants do not influence the develop-
ment of non-atopic eczema in our adult material.
Table III. Results of Pedigree Disequilibrium Test for filaggrin variants in the Swedish eczema families
Trait
R501X 2282del4 Combined
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Eczema 2.68 (1.34–5.33) 1.5×10–5 1.85 (1.24–2.76) 2.9×10–5 1.81 (1.31–2.50) 1.3×10–6
Atopic eczema 4.33 (1.88–9.94) 2.6×10–7 2.22 (1.41–3.47) 4.1×10–6 2.21 (1.50–3.25) 9.5×10–8
Non-atopic eczema 2.07 (0.78–5.47) NS 0.99 (0.54–1.80) NS 1.07 (0.62–1.84) NS
Early onset 4.37 (1.79–10.64) 2.8×10–7 2.14 (1.41–3.23) 4.2×10–5 2.09 (1.46–2.97) 1.2×10–6
Severe eczema 5.29 (3.32–8.84) 1.3×10–12 6.34 (1.90–21.2) 1.5×10–7 4.73 (1.98–11.29) 3.6×10–8
Allergic asthma 3.94 (1.12–13.87) 8.4×10–6 3.85 (1.97–7.51) 2.4×10–7 3.58 (1.99–6.42) 6.5×10–9
Allergic rhinoconjunctivitis 5.07 (1.47–17.46) 2.7×10–12 1.97 (1.28–3.03) 7.8×10–5 2.03 (1.39–2.97) 7.0×10–7
Raised total IgE 4.33 (1.26–14.81) 8.8×10–6 1.85 (1.14–2.98) 0.0066 1.93 (1.24–2.99) 0.00054
OR: odds ratio of minor allele relative to major allele. OR for R501X in the severe eczema phenotype was calculated in a χ2 test. NS: non-significant. CI: 
confidence interval,
0%
20%
40%
60%
80%
100%
Atopic
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Severe
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Fig. 1. Filaggrin genotype and correlation to phenotype frequencies with 
95% confidence intervals in eczema-affected siblings.
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We found a higher OR for 2282del4 (6.34 (1.90–
21.2)) and R501X (5.29 (3.32–8.84)) when analysing 
the subgroup with the severe eczema phenotype, and 
43.4% of the individuals in this subgroup were carriers 
of an FLG null allele. As to FLG null carriers, 67% of 
the homozygote carriers and 42% of the heterozygote 
carriers belonged to this phenotype group. Only 16% 
of wild-type carriers of FLG were classified into the 
severe-eczema phenotype (Fig. 1). Our results may 
therefore support the hypothesis that individuals with 
eczema who carry FLG null alleles could be more likely 
to suffer from a persistent severe disease. Two previous 
studies also present a high frequency of carriers of 
FLG null alleles, 29.7% and 42%, among patients with 
persistent eczema and an early onset (25, 26). In our 
material, where 78% of the patients had early onset, 
we found a null allele carrier frequency of 20.6% in 
the subgroup with early onset (≤ 2 years of age) and 
the effect of carrying a FLG null allele on early-onset 
phenotype was only marginal (Fig. 1).
Several studies have indicated that FLG variants may 
be susceptibility factors for asthma (9, 21, 22, 24, 25), 
rhinoconjunctivitis (21, 25) and raised total IgE (22, 
25) in eczema patients.
A similar pattern of association to allergic asthma, 
allergic rhinoconjunctivitis and raised total IgE was 
also seen in our material. However, other studies have 
shown that there is no association with either asthma or 
rhinoconjunctivitis when eczema affected individuals 
are excluded from the study populations (9, 21, 24). 
Larger cohorts ascertained outside the context of eczema 
are needed to resolve the role of FLG variants in the 
pathogenesis of these phenotypes.
In conclusion, our results support an important role 
for the FLG gene variants R501X and 2282del4 in the 
development and severity of atopic eczema. Further-
more, by causing a dysfunctional skin barrier leading 
to increased epidermal allergen transfer, these variants 
could also play an important role in the subsequent 
progression into eczema-associated phenotypes. 
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